FCN-437c
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for FCN-437c, covering 2020-07-27 to 2022-07-06. Get the full timeline:
Most recent: Clinical Trial Update: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. [Phase 3]